Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Pfizer Inc. < Previous 1 2 3 4 5 6 7 8 9 Next > U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B April 26, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer Declares Second-Quarter 2024 Dividend April 24, 2024 From Pfizer Inc. Via Business Wire Tickers PFE European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options April 22, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25 April 11, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease April 09, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts March 20, 2024 From Pfizer Inc. Via Business Wire Tickers PFE European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease March 13, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) March 12, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference March 05, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth February 29, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults February 29, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference February 26, 2024 From Pfizer Inc. Via Business Wire Tickers PFE European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis February 19, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer Invites Public to Register for Webcast of Pfizer Oncology Innovation Day February 15, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Breaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care Disparities February 05, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance January 30, 2024 From Pfizer Inc. Via Business Wire Tickers PFE European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer January 26, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation January 10, 2024 From Pfizer Inc. Via Business Wire Tickers PFE TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer January 09, 2024 From Pfizer Inc. Via Business Wire Tickers GMAB PFE European Commission Approves Pfizer’s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer January 08, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference January 02, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts December 19, 2023 From Pfizer Inc. Via Business Wire Tickers PFE PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer December 15, 2023 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer Declares First-Quarter 2024 Dividend December 14, 2023 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer Completes Acquisition of Seagen December 14, 2023 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer Provides Full-Year 2024 Guidance December 13, 2023 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen December 12, 2023 From Pfizer Inc. Via Business Wire Tickers PFE FDA and EMA Accept Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B December 11, 2023 From Pfizer Inc. Via Business Wire Tickers PFE Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B December 09, 2023 From Pfizer Inc. Via Business Wire Tickers PFE European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma December 08, 2023 From Pfizer Inc. Via Business Wire Tickers PFE < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.